References

1. Burtin P, Von Kleist S, Rapp W, Loisillier F, Bonatti A, Grabar P. Auto-anticorp chez les cancéreux. Presse Med 1965;73:2599-2603.

2. Wilkinson PC, Zeromski J. Immunofluorescent detection of antibodies against neurones in sensory carcinomatous neuropathy. Brain 1965;88:529-583.

3. Shiku H, Takahashi T, Oettgen HF, Old LJ. Cell surface antigens of human malignant melanoma. II. Serological typing with immune adherence assays and definition of two new surface antigens. J Exp Med 1976;144:873-881.

4. Pfreundschuh M, Shiku H, Takahashi T, Whitmore WF, Oettgen HF, Old LJ. Serological analysis of cell surface antigens of malignant human brain tumors. Proc Natl Acad Sci USA 1978;75:5122-5126.

5. Ueda R, Shiku H, Pfreundschuh M, Takahashi T, Whitmore WF, Oettgen HF, Old LJ. Cell surface antigens of human renal cancer defined by autologous typing. J Exp Med 1979;150:564-579.

6. Old LJ. Cancer immunology: the search for specificity - G.H.A. Lowes memorial lecture. Cancer Res 1981;41:361-375.

7. Cheever MA, Disis ML, Bernhard H, Gralow JR, Hand SL, Huseby ES, Qin HL, Takahashi M, Chen W. Immunity to oncogenic proteins. Immunol Rev 1995;145:33-59.

8. Kotera Y, Fontenot JD, Pecher G, Metzgar RS, Finn OJ. Humoral immunity against a tandem repeat epitope of human mucin MUC-1 in sera from breast, pancreatic and colon cancer patients. Cancer Res 1994;54:2856-2860.

Sahin U, Ttireci O, Schmitt H, Cochlovius B, Johannes T, Schmits R, Stenner F, Luo G, Schobert I, Pfreundschuh M. Human neoplasms elicit multiple specific immune responses in the autologous host. Proc Natl Acad Sci USA 1995;92:11810-11813. Ttireci O, Sahin U, Pfreundschuh M: Serological analysis of human tumor antigens: molecular definition and implications. Mol Med Today 1997;3:342-349.

Sahin U, Tiireci O, Pfreundschuh M. Serological identification of human tumor antigens. Curr Opin Immunol 1997;9:709-716.

Old LJ, Chen YT. New paths in human cancer serology. J Exp Med 1998;187:1163-1167. Ehrlich R, Witz IP. Natural killer cells and naturally occurring antibodies as representative of natural tumor immunity. Pathobiol Ann 1982;12:85-113. Witz IP, Agassy-Cahalon L. Do naturally occuring antibodies play a role in progression and proliferation of tumor cells? Int Rev Immunol 1988;3:133-145. Cahalon L, Korem S, Gonen B, Puri J, Smorodin-sky NI, Witz IP. Autoantibody-mediated regulation of tumor growth. Ann NY Acad Sci 1992;621:393-408. Disis ML, Pupa SM, Gralow JR, Dittadi R, Menard S, Cheever MA. High-titer HER-2/neu protein-specific antibody can be detected in patients with early-stage breast cancer. J Clin Oncol 1997;15:3363-3367. Takahashi M, Chen W„ Burd DR, Disis ML, Huseby ES, Qin H, McCahill L, Nelson H, Shimada H, Okuno K, Yasutomi M, Peace DJ, Cheevers MA. Antibody to ras proteins in patients with colon cancer. Clin Cancer Res 1995;1:1071-1077.

Ben-Mahrez K, Sorokine I, Thierry D, Kawasumi T, Ishii S, Salmon R, Kohiyama M. Circulating antibodies against c-myc oncogene product in sera of colorectal cancer patients. Int J Cancer 1990;46:35-38.

Deguchi Y, Negoro S, Kishimoto S. Autoantibody to human c-myc oncogene product in autoimmune patients' sera. Int Arch Allergy Appl Immunol 1988;87:313-316.

LaFond RE, Eaton RB, Watt RA, Villee CA, Actor JK, Schur PH. Autoantibodies to c-myc protein: elevated levels in patients with African Burkitt's lymphoma and normal Ghanians. Autoimmunity 1992;13:215~ 224.

Yamamoto A, Shimizu E, Ogura T, Sone S. Detection of auto-antibodies against L-myc oncogene products in sera from lung cancer patients. Int J Cancer 1996;69:283-289.

Yamamoto A, Shimizu E, Sumitomo K, Shinohara A, Namikawa O, Uehara H, Sone S. L-myc over-

expression and detection of auto-antibodies against L-myc in both the serum and pleural effusion from a patient with non-small cell lung cancer. Int Med 1997;36:724-727.

23. Sorokine I, Ben-Mahrez K, Bracone A, Thierry D, Ishii S, Imamoto F, Kohiyama M. Presence of circulating anti-c-myb oncogene product antibodies in human sera. Int J Cancer 1991;47:665-669.

24. Hansen R, Oren M. p53: from inductive signal to cellular effect. Curr Opin Genet Dev 1997;7:46-51.

25. Hall PA, Lane DP. Tumour suppressors: a developing role for p53? Current Biol 1997;7:144-147.

26. Nigro JM, Baker SJ, Preisinger AC, Jessup JM, Hosteter R, Cleary K, Bigner SH, Davidson N, Baylin S, Devilee P. Mutation in the p53 gene occur in diverse human tumour types. Nature 1989;342:705-708.

27. Hoi 1 stein M, Sidransky D, Vogelstein B, Harris CC. p53 mutations in human cancer. Science 1991;253:49-53.

28. Crawford LV, Pim DC, Bulbrook RD. Detection of antibodies against the cellular protein p53 in sera from patients with breast cancer. Int J Cancer 1982;30:403-408.

29. Lubin R, Schlichtholz B, Teillaud JL, Garay E, Bussel A, Wild CP. p53 antibodies in patients with various types of cancer: Assay, identification, and characterization. Clin Cancer Res 1995;1:1463-1469.

30. Montenarh M. Humoral immune response against p53 in human malignancies. In: Conrad K, Hum-bel RL, Meurer M, Shoenfeld Y, Tan EM, eds., Pathogenic and Diagnostic Relevance of Autoantibodies. Lengerich, Berlin: Pabst Science Publishers, 1998;377-394.

31. Lubin R, Zalcman G, Bouchet L, Tredanel J, Legros Y, Cazals D, Hirsch A, Soussi T. Serum p53 antibodies as early markers of lung cancer. Nature Med 1995;1:701-702.

32. Trivers GE, Cawley HL, De Benedetti VMG, Hollstein M, Marion MJ, Bennett WP, Hoover ML, Prives C, Tamburro C, Harris CC. Anti-p53 antibodies in sera of workers occupationally exposed to vinyl chloride. J Natl Cancer Inst 1995;87:1400-1407.

33. Trivers GE, De Benedetti VMG, Cawley HL, Caron G, Harrington AM, Bennett WP, Jett JR, Colby TV, Tazelaar H, Pairolero P, Miller RD, Harris CC. Anti-p53 antibodies in sera from patients with chronic obstructive pulmonary disease can predate a diagnosis of cancer. Clin Cancer Res 1996;2:1767-1775.

34. Rohayem J, Conrad K, Frey M, Mehlhom J, Frank KH. Autoantibodies—predictive parameters of tumor development? In: Conrad K, Humbel RL, Meurer M, Shoenfeld Y, Tan EM, eds., Pathogenic and Diagnostic Relevance of Autoantibodies. Lengerich, Berlin: Pabst Science Publishers, 1998;412^tl4.

Tomer Y, Sherer Y, Shoenfeld Y. Autoantibodies, autoimmunity and cancer (Review). Oncol Rep 1998;5:753-761.

IARC. Silica, some silicates, cool dust and para-aramid fibrils. Lyon: IARC Monographs on the evaluation of carcinogenic risk to human 68; 1997. Tan EM. Autoantibodies in pathology and cell biology. Cell 1991;67:841-842.

Hunter T, Pines J. Aberrant expression of cyclins may be intimately associated with the neoplastic process. Cell 1991;66:1071-1074.

Gong J, Ardett B, Traganos F, Darzynkiewicz Z. Unscheduled expression of cyclin B1 and cyclin E in several leukemic and solid tumor cell lines. Cancer Res 1994;54:4285-4288.

Buckley MF, Sweeney KJ, Hamilton JA, Sini RL, Manning DL, Nicholson RI, de Fazio A, Watts CK, Musgrove EA, Sutherland RL. Expression and amplification of cyclin genes in human breast cancer. Oncogene 1993;8:2117-2133. Wang A, Yoshimi N, Ino N, Tanaka T, Mori H. Overexpression of cyclin B1 in human colorectal cancers. J Cancer Res Clin Oncol 1997;123:124-127. Covini G, Chan EKL, Nishioka M, Morshed SA, Reed SI, Tan EM. Immune response to cyclin B1 in hepatocellular carcinoma. Hepatol 1997;25:75-80.

Landberg G, Tan EM. Characterization of a DNA-binding nuclear autoantigen mainly associated with S phase and G2 cells. Exp Cell Res 1994;212:255-261. Muro Y, Chan EKL, Landberg G, Tan EM. A cell-cycle nuclear autoantigen containing WD-40 motifs expressed mainly in S and G2 phase cells. Biochem Biophys Res Commun 1995;207:1029-1037. Casiano CA, Landberg G, Ochs R, Tan EM. Autoantibodies to a novel cell cycle-regulated protein that accumulates in the nuclear matrix during S phase and is localized in the kinetochores and spindle midzone during mitosis. J Cell Sci 1993;106:1045-1056.

Rattner JB, Rao A, Fritzler MJ, Valencia DW, Yen TJ. CENP-F is a ca. 400 kDa kinochore protein that exhibits a cell-cycle dependent localization. Cell Motil Cytoskeleton 1993;26:214-226. Humbel RL. Autoantibodies to the cellular mitotic apparatus. Immunobiology 1986; 173:211. Rattner JB, Rees J, Whitehead CM, Casiano CA, Tan EM, Humbel RL, Conrad K, Fritzler M. High frequency of neoplasia in patients with autoantibodies to centromere protein CENP-F. Clin Invest Med 1997;20:308-319.

Casiano CA, Humbel RL, Peebles C, Covini G, Tan EM. Autoimmunity to the cell cycle-dependent centromere protein p330d/CENP-F in disorders associated with cell proliferation. J Autoimmun 1995;8:575-586.

50. Gosrau G, Conrad K, Frank KH. Non-organspecific autoantibodies in tumor patients. In: Conrad K, Humbel RL, Meurer M, Shoenfeld Y, Tan EM, eds., Pathogenic and Diagnostic Relevance of Autoantibodies. Lengerich, Berlin: Pabst Science Publishers, 1998;415—416.

51. Landberg G, Erlanson M, Roos G, Tan EM, Casiano CA. Nuclear autoantigen p330d/CENP-F: A marker for cell proliferation in human malignances. Cytometry 1996;25:90-98.

52. Heck MMS, Earnshaw WC. Topoisomerase II: A specific marker for cell proliferation. J Cell Biol 1986;103:2569-2581.

53. Zwelling LA. DNA topoisomerase II as a target of antineoplastic drug therapy. Cancer Met Rev 1985;4:263-276.

54. Francis GE. Leukaemogenesis: a postulated mechanism involving tyrosine protein kinase and DNA topoisomerase. Med Hypoth 1987;22:223-231.

55. Imai H, Furuta K, Landberg G, Kiyosawa K, Liu LF, Tan EM. Autoantibodies to DNA topoisomerase II in primary liver cancer. Clin Cancer Res 1995;1:417-422.

56. Imai H, Ochs RL, Kiyosawa K, Furuta S, Nakamura RM, Tan EM. Nucleolar antigens and autoantibodies in hepatocellular carcinoma and other malignancies. Am J Pathol 1992;140:859-870.

57. Imai H, Chan EKL, Kiyosawa K, Fu XD, Tan EM. Novel nuclear autoantigen with splicing factor motifs identified with antibody from hepatocellular carcinoma. J Clin Invest 1993;92:2419-2426.

58. Imai H, Fritzler MJ, Neri R, Bombardieri S, Tan EM, Chan EKL. Immunocytochemical characterization of human NOR-90 (upstream binding factor) and associated antigens reactive with autoimmune sera. Mol Biol Rep 1994;19:115-124.

59. Covini G, von Mühlen CA, Pacchetti S, Colombo M, Chan EKL, Tan EM. Diversity of antinuclear antibody responses in hepatocellular carcinoma. J Hepatol 1997;26:1255-1265.

60. Stockert E, Jäger E, Chen YT, Scanlan MJ, Gout I, Karbach J, Arand M, Knuth A, Old LJ. A survey of the humoral immune response of cancer patients to a panel of human tumor antigens. J Exp Med 1998;187:1349-1354.

61. Jäger E, Chen YT, Drijfhout JW, Karbach J, Ring-hoffer M, Jäger D, Arand M, Wada H, Noguchi Y, Stockert E, Old LJ, Knuth A. Simultaneous humoral and cellular immune response against cancer-testis antigen NY-ESO-1: Definition of human histocompatibility leukocyte antigen (HLA)-A2-binding peptide epitopes. J Exp Med 1998;187:265-270.

62. Posner JB, Dalmau J. Paraneoplastic syndromes. Curr Opin Immunol 1997;9:723-729.

63. Lang B, Vincent A. Autoimmunity to ion-channels and other proteins in paraneoplastic disorders. Curr Opin Immunol 996;8:865-871.

64. Lennon VA. Calcium channel and related paraneoplastic disease autoantibodies. In: Peter JB, Shoen-feld Y, eds., Autoantibodies. Amsterdam: Elsevier, 1996;139-146.

65. Furneaux HM. Neuronal nuclear autoantibodies, Type 1 (Hu). In: Peter JB, Shoenfeld Y, eds., Autoantibodies. Amsterdam: Elsevier, 1996;551-554.

66. Dalmau JO, Posner JB. Purkinje cell autoantibodies, type 1 (Yo). In: Peter JB, Shoenfeld Y, eds., Autoantibodies. Amsterdam:Elsevier, 1996;655-659.

67. Graus F, Dalmou J, Rene R, Tora M, Malats N, Ver-schuuren JJ, Cardenal F, Vinolas N, del Muro G, Vadell C, Mason WP, Rosell R, Posner JB, Real FX. Anti-Hu antibodies in patients with small-cell lung cancer: association with complete response to therapy and improved survival. J Clin Oncol 1997;15:2866-2872.

68. Drlicek M, Bianchi G, Bogliun G, Casati B, Grisold W, Kolig C, Liszka-Setinek U, Marzorati L, Wondrusch E, Cavaletti G. Antibodies of the anti-Yo and anti-Ri type in the absence of paraneoplastic neurological syndromes: a long-term survey of ovarian cancer patients. J Neurol 1997;244:85-89.

69. Voltz RD, Albrich WC, Nägele A, Schümm F, Wick M, Freiburg A, Gautel M, Thaler HT, Aarli J, Kirchner T, Hohlfeld R. Paraneoplastic myasthenia gravis: Detection of anti-MGT30 (titin) antibodies predict thymic epithelial tumor. Neurol 1997;49:1454-1457.

70. Mygland A, Aarli JA, Matre G, Gilhus NE. Ryanodine receptor (RyR) antibodies are detected in about 50% of patients with myasthenia gravis who have a thymoma. J Neurol Neurosurg Psychiat 1994;57:843-846.

71. Dropcho EJ. Antiamphiphysin antibodies with small-cell lung carcinoma and paraneoplastic encephalomyelitis. Ann Neurol 1996;39:659-667.

72. Sela O, Shoenfeld Y. Cancer in autoimmune diseases. Semin Arthrit Rheum 1988;18:77-87.

73. Fishman P. Autoimmunity and cancer. Isr J Med 30 1994;30:15-19.

74. Huminer D, Tomer Y, Pitlick S, Shoenfeld Y. Autoantibodies in cancer patients: are they tumor related or age related? Autoimmunity 1990;5:232-233.

75. Swissa M, Amital-Teplitzky H, Haim N, Cohen Y, Shoenfeld Y. Autoantibodies in neoplasia. An unresolved enigma. Cancer 1990;65:2554-2558.

76. Boyeldieu D, Rouquette-Gally AM, Laugier A, Abuaf N. Anticorp anti-centromere, CREST et cancer. Presse Med 1987;16;1924-1925.

77. Kuwana M, Fujii T, Mimori T, Kaburaki J. Enhancement of anti-DNA topoisomerase I autoantibody response after lung cancer in patients with systemic sclerosis. A report of two cases. Arthrit Rheum 1996;39:686-691.

78. Zuber M, Götzen R, Filler I. Clinical correlation of anticentromere antibodies. Clin Rheumatol 1994;13:427-432.

79. Conrad K, Stahnke G, Liedvogel B, Mehlhorn J, Barth J, Blasum C, Altmeyer P, Sönnichsen N, Frank KH. Anti-CENP-B response in sera of uranium miners exposed to quartz dust and patients with possible development of systemis sclerosis. J Rheumatol 1995;22:1286-1294.

80. Schüttmann W. Schneeberg lung disease and uranium mining in the Saxon Ore Mountains (Erzgebirge). Am J Industr Med 1993;23:355-368.

81. Conrad K, Frank KH, Mehlhorn J. Kollagenose-typische Autoantikörper in Seren von quarzstaubex-ponierten Uranerzbergarbeitern. Diagnostische, prognostische und ätiopathogenetische Bedeutung in Bezug auf die Entwicklung systemischer Autoimmunerkrankungen. In: Conrad K, ed., Autoantikörper. Lengerich, Berlin: Pabst Science Publishers, 1998;250-288.

82. Tan EM, Cohen AS, Fries JF, Masi AT, Mc-Shane DJ, Rothfield NF, Green Schaller J.Talal N, Winchester RJ. The revised criteria for the classification of systemic lupus erythematosus. Arthrit Rheum 1982;25:1271-1277.

83. Conrad K, Mehlhorn J, Lüthke K, Dörner T, Frank KH. Systemic lupus erythematosus after heavy exposure to quartz dust in uranium mines: clinical and serological characteristics. Lupus 1996;5:62-69.

84. Green JA, Mudenda B, Jenkins J, Leinster SJ, Tarun-ina M, Green B, Robertson L. Serum p53 autoantibodies: incidence in familial breast cancer. Eur J Cancer 1994;30A:580-584.

85. Tan EM. Autoantibodies as diagnostic markers and messengers form the immune system. In: Conrad K, Humbel RL, Meurer M, Shoenfeld Y, Tan EM, eds., Pathogenic and Diagnostic Relevance of Autoantibodies. Lengerich, Berlin: Pabst Science Publishers, 1998;20—31.

© 2000 Elsevier Science B. V. All rights reserved.

Cancer and Autoimmunity

Y. Shoenfeld and M. E. Gershwin, editors

10 Ways To Fight Off Cancer

10 Ways To Fight Off Cancer

Learning About 10 Ways Fight Off Cancer Can Have Amazing Benefits For Your Life The Best Tips On How To Keep This Killer At Bay Discovering that you or a loved one has cancer can be utterly terrifying. All the same, once you comprehend the causes of cancer and learn how to reverse those causes, you or your loved one may have more than a fighting chance of beating out cancer.

Get My Free Ebook


Post a comment